
Around 100,000 fewer colonoscopies expected to take place each year following updated NICE guidance
Tens of thousands of people a year could be spared the need for a colonoscopy following new guidance from NICE.
All NICE products on blood and bone marrow cancers. Includes any guidance, advice and quality standards.
We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
Published advice on this topic (4)
Set out priority areas for quality improvement in health and social care.
Published quality standards on this topic (2)
Review the evidence across broad health and social care topics.
Reviews the clinical and cost-effectiveness of new treatments.
Review new diagnostic technologies for adoption in the NHS.
Assessments of whether procedures are safe enough and work well enough for wider use in the NHS.
Review the best available evidence for selected medicines.
Review the evidence and likely costs of medical devices and technologies.
Guidance, quality standards and advice being developed.
Guidance and quality standards awaiting development.
Guidance in topic selection.
Tens of thousands of people a year could be spared the need for a colonoscopy following new guidance from NICE.
Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.
NICE has agreed a managed access agreement, via the Cancer Drugs Fund with manufacturer Kite, so more data can be collected while patients can access the treatment.
Examples of how our guidance and standards have been put into practice in the NHS, local authorities, voluntary sector and a range of other organisations.
Showing 3 of 3 shared learning examples for this topic: